Compare Quest Diagnostics Inc (DGX) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs FuelCell Energy Inc — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while FuelCell Energy Inc trades at $20.27 (market cap $1.71B). The key difference: Quest Diagnostics Inc is far larger — about 13.3× FuelCell Energy Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| DGX | FCEL | |
|---|---|---|
Market Cap | $22.80B | $1.71B |
Sector | Health | Industrials |
52-Week High | $216.02 | $36.01 |
52-Week Low | $166.42 | $3.92 |
Enterprise Value | $28.82B | $1.56B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
FuelCell Energy (FCEL) trades at $19.08, down 9.27% in the last session, as the stock consolidates following recent volatility. The company reported mixed Q1 2026 results with an earnings miss but continues to show revenue growth, with 2025 revenue reaching $158.16M. Technical indicators show a bearish trend with key support at $17-18 levels. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225 million stock offering that caused temporary dilution concerns.
FCEL presents a high-risk opportunity with strong growth potential in the fuel cell sector but faces significant fundamental challenges. The company maintains negative profitability metrics and cash burn, though recent partnerships and data center demand provide catalysts. Analyst consensus is mixed with a $20.75 price target representing 8.8% upside, but investors should weigh the growth narrative against persistent losses and dilution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
